RAPGEF5

Across TCGA pan-cancer cohorts, RAPGEF5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAPGEF5 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RAPGEF5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAPGEF5 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

STAD, LIHC, and SKCM are the cancer types where RAPGEF5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.162	0.586	<.001	36	view →
LIHC	OS	Median	All	0.028	0.775	<.001	18	view →
SKCM	DFS	Median	III,IV	0.167	0.653	.024	9	view →
SCLC	OS	Median	III,IV	1.000	0.413	.046	7	view →
BLCA	OS	Median	III,IV	0.211	0.581	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAPGEF5–STAD (OS)

Open the STAD breakdown →